2023
The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso
Guissou R, Amaratunga C, de Haan F, Tou F, Cheah P, Yerbanga R, Moors E, Dhorda M, Tindana P, Boon W, Dondorp A, Ouédraogo J. The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso. Malaria Journal 2023, 22: 269. PMID: 37705004, PMCID: PMC10498571, DOI: 10.1186/s12936-023-04705-0.Peer-Reviewed Original ResearchConceptsDepth interviewsGroup discussionsNational policy makersDrug marketBurkina FasoFocus group discussionsPolicy publicationsPublic policyCommunity membersFunding systemPolicy makersAfrican countriesPolicyAnti-malarial policyMarket characteristicsAnti-malarial marketInterviewsRepresentative sampleGrey literatureMarketFasoPerspectiveEmergenceTerms of availabilityDiscussionCost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso
Diawara H, Bocoum F, Dicko A, Levin A, Lee C, Koita F, Ouédraogo J, Guissou R, Yabré S, Traoré S, Morgan W, Pecenka C, Baral R. Cost of introducing and delivering malaria vaccine (RTS,S/AS01E) in areas of seasonal malaria transmission, Mali and Burkina Faso. BMJ Global Health 2023, 8: e011316. PMID: 37068848, PMCID: PMC10111920, DOI: 10.1136/bmjgh-2022-011316.Peer-Reviewed Original ResearchConceptsVaccine deliverySeasonal vaccinationMalaria vaccineMalaria transmissionSeasonal malaria transmissionRoutine Expanded ProgrammeResource use dataRoutine EPINew vaccine introductionSeasonal malariaVaccine introductionMain cost driversHealth facilitiesExpanded ProgrammeVaccine priceVaccine rolloutMass campaignsService deliveryYoung childrenVaccinationCost consequencesBurkina FasoFinancial costsVaccineDelivery approach
2022
Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria
Tindana P, Guissou R, Bolarinwa O, Tou F, de Haan F, Dhorda M, Dondorp A, Amaratunga C, Mokuolu O, Ouedraogo J, Cheah P. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLOS ONE 2022, 17: e0273249. PMID: 36083995, PMCID: PMC9462557, DOI: 10.1371/journal.pone.0273249.Peer-Reviewed Original ResearchConceptsTriple artemisinin-based combination therapiesArtemisinin-based combination therapyCombination therapyArtemisinin resistanceUncomplicated Plasmodium falciparum malariaDrug resistancePlasmodium falciparum malariaMalaria-endemic countriesPartner drug resistanceAdditional side effectsUncomplicated malariaFalciparum malariaTreatment optionsEndemic countriesPediatric diseasesSide effectsACT failureMalariaTherapyBurkina FasoFocus group discussionsEthical considerationsTreatmentQualitative studyStakeholder engagement activitiesFactors Influencing Second and Third Dose Observance during Seasonal Malaria Chemoprevention (SMC): A Quantitative Study in Burkina Faso, Mali and Niger
Somé A, Zongo I, Sagara I, Ibrahim A, Ahanhanzo C, Agbanouvi-agassi E, Sayi D, Toe L, Kabré Z, Nikiéma F, Bazié T, Ouédraogo S, Sombié I, Dicko A, Adehossi E, Ouédraogo J, Dabiré K. Factors Influencing Second and Third Dose Observance during Seasonal Malaria Chemoprevention (SMC): A Quantitative Study in Burkina Faso, Mali and Niger. Tropical Medicine And Infectious Disease 2022, 7: 214. PMID: 36136625, PMCID: PMC9503675, DOI: 10.3390/tropicalmed7090214.Peer-Reviewed Original ResearchDelivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study
Ward C, Phillips A, Oresanya O, Olisenekwu G, Arogunade E, Moukénet A, Beakgoubé H, De Paul Allambademel V, Compaoré C, Traoré A, Ouedraogo J, Compaoré Y, Zongo I, Donovan L, Decola M, Smith H, Baker K. Delivery of seasonal malaria chemoprevention with enhanced infection prevention and control measures during the COVID-19 pandemic in Nigeria, Burkina Faso and Chad: a cross-sectional study. Malaria Journal 2022, 21: 103. PMID: 35331248, PMCID: PMC8943494, DOI: 10.1186/s12936-022-04091-z.Peer-Reviewed Original ResearchConceptsCross-sectional studyIPC measuresMalaria chemopreventionInfection preventionMethodsA cross-sectional studyEnhanced infection preventionSeasonal malaria chemopreventionCoronavirus disease 2019 (COVID-19) transmissionHigh malaria transmissionOptimal hand hygiene practicesHand hygiene practicesProportion of indicationsCOVID-19 pandemicEarly community engagementFirst doseHand hygieneWHO guidanceMalaria transmissionBurkina FasoHand washingControl measuresHygiene practicesProtective equipmentAdherenceBlister packsUse of different cotton pest control strategies (conventional, organic and transgenic) had no impact on insecticide resistance in Anopheles gambiae s.l. populations in Burkina Faso, West Africa
Namountougou M, Soma D, Sangare I, Djouaka R, Hien A, Kientega M, Kaboré A, Sawadogo S, Millogo A, Balboné M, Baldet T, Ouedraogo J, Martin T, Simard F, Ouedraogo G, Diabaté A, Gnankiné O, Dabiré R. Use of different cotton pest control strategies (conventional, organic and transgenic) had no impact on insecticide resistance in Anopheles gambiae s.l. populations in Burkina Faso, West Africa. International Journal Of Pest Management 2022, 1-12. DOI: 10.1080/09670874.2022.2051642.Peer-Reviewed Original Research
2021
To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
de Haan F, Bolarinwa O, Guissou R, Tou F, Tindana P, Boon W, Moors E, Cheah P, Dhorda M, Dondorp A, Ouedraogo J, Mokuolu O, Amaratunga C. To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies? PLOS ONE 2021, 16: e0256567. PMID: 34464398, PMCID: PMC8407563, DOI: 10.1371/journal.pone.0256567.Peer-Reviewed Original ResearchConceptsAfrican countriesTriple artemisinin-based combination therapiesKey actor groupsMarket prospectsBurkina FasoActor groupsInnovation systemRegulatory arrangementsDepth interviewsInternational fundersArtemisinin-based combination therapyProfit motivesQualitative studySoutheast AsiaGroup discussionsCountry levelAfrican countiesCurrent artemisinin-based combination therapiesLarger communityCountriesDrug marketAcceptability issuesBroad implicationsWorld Health OrganizationMarket readinessPersistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso
Beshir K, Diallo N, Somé F, Sombie S, Zongo I, Fofana B, Traore A, Dama S, Bamadio A, Traore O, Coulibaly S, Maurice O, Diarra A, Kaboré J, Kodio A, Togo A, Dara N, Coulibaly M, Dao F, Nikiema F, Compaore Y, Kabore N, Barry N, Soulama I, Sagara I, Sirima S, Ouédraogo J, Djimde A, Sutherland C. Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00873-21. PMID: 34060901, PMCID: PMC8284475, DOI: 10.1128/aac.00873-21.Peer-Reviewed Original ResearchConceptsArtemether-lumefantrineClinical episodesFirst treatment episodeComplete parasite clearanceDrug treatment groupPlasmodium falciparum parasitemiaQuantitative PCRMalaria transmission intensityEvaluable patientsParasitological efficacyParasite clearanceTreatment failureSubmicroscopic parasitemiaTreatment episodesTreatment outcomesTreatment groupsBetter efficacyDay 42Short intervalsH posttreatmentParasitemiaRegimensPatientsBurkina FasoTransmission intensityNutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria
de Wit M, Cairns M, Compaoré Y, Sagara I, Kuepfer I, Zongo I, Barry A, Diarra M, Tapily A, Coumare S, Thera I, Nikiema F, Yerbanga R, Guissou R, Tinto H, Dicko A, Chandramohan D, Greenwood B, Ouedraogo J. Nutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria. Malaria Journal 2021, 20: 274. PMID: 34158054, PMCID: PMC8220741, DOI: 10.1186/s12936-021-03802-2.Peer-Reviewed Original ResearchConceptsClinical malaria incidenceSeasonal malaria chemopreventionMalaria transmission seasonClinical malariaNutritional statusMalaria incidenceMalaria chemopreventionSubsequent incidenceTransmission seasonMalaria seasonNutritional indicatorsEffects of malnutritionYoung childrenSymptomatic malariaScreening visitArm circumferenceLower incidenceModerate wastingHigh incidenceRandom effects Poisson modelBurkina FasoInsecticidal netsMalaria controlMalnutritionMalariaThe Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali
Phiri M, Cairns M, Zongo I, Nikiema F, Diarra M, Yerbanga R, Barry A, Tapily A, Coumare S, Thera I, Kuepfer I, Milligan P, Tinto H, Dicko A, Ouédraogo J, Greenwood B, Chandramohan D, Sagara I. The Duration of Protection from Azithromycin Against Malaria, Acute Respiratory, Gastrointestinal, and Skin Infections When Given Alongside Seasonal Malaria Chemoprevention: Secondary Analyses of Data from a Clinical Trial in Houndé, Burkina Faso, and Bougouni, Mali. Clinical Infectious Diseases 2021, 73: e2379-e2386. PMID: 33417683, PMCID: PMC8492219, DOI: 10.1093/cid/ciaa1905.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMass drug administrationMalaria chemopreventionPlacebo-controlled trialEvidence of protectionDuration of protectionHospital admissionAcute respiratoryIllness episodesWeeks postadministrationClinical trialsSkin infectionsSkin conditionsDrug AdministrationProfile of protectionAzithromycinPoisson regressionChild survivalSecondary analysisBurkina FasoDifferent causesExtent of protectionChemopreventionMalariaAdministrationHemoglobin change following first line treatment of uncomplicated falciparum malaria with artemether-lumefantrine and artesunate-amodiaquine in Burkina Faso
Zongo I, Compaore Y, Ouedraogo G, Nikiema F, Some F, Ouedraogo J. Hemoglobin change following first line treatment of uncomplicated falciparum malaria with artemether-lumefantrine and artesunate-amodiaquine in Burkina Faso. PAMJ Clinical Medicine 2021, 5 DOI: 10.11604/pamj-cm.2021.5.11.23991.Peer-Reviewed Original Research
2020
Effect of adding azithromycin to the antimalarials used for seasonal malaria chemoprevention on the nutritional status of African children
Gore‐Langton G, Cairns M, Compaoré Y, Sagara I, Kuepfer I, Zongo I, de Wit M, Barry A, Diarra M, Tapily A, Coumare S, Thera I, Nikiema F, Yerbanga R, Guissou R, Tinto H, Dicko A, Chandramohan D, Greenwood B, Ouedraogo J. Effect of adding azithromycin to the antimalarials used for seasonal malaria chemoprevention on the nutritional status of African children. Tropical Medicine And International Health 2020, 25: 740-750. PMID: 32166877, DOI: 10.1111/tmi.13390.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria transmission seasonMalaria chemopreventionNutritional statusTransmission seasonTreatment armsAddition of azithromycinEffect of azithromycinNutritional status indicatorsCross-sectional surveyHospital admissionRecent trialsMass administrationAnthropometric measurementsChronic malnutritionAzithromycinAfrican childrenChemopreventionNutritional outcomesBurkina FasoContinuous outcomesStudy periodMode of actionProtocol analysisYoung childrenEfficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change
Zongo I, Compaoré Y, Nikiéma F, Zongo M, Barry N, Somé F, Kaboré N, Ouédraogo J. Efficacy of artemether-lumefantrine and artesunate-amodiaquine as first line therapy of uncomplicated malaria in Burkina Faso, 11 years after policy change. Pan African Medical Journal 2020, 35: 68. PMID: 32537072, PMCID: PMC7250195, DOI: 10.11604/pamj.2020.35.68.20849.Peer-Reviewed Original ResearchConceptsFirst-line therapyLine therapyUncomplicated malariaPolymerase chain reactionTreatment efficacyEarly treatment failureGood tolerability profileFirst-line treatmentParasitological responsePrimary endpointTolerability profileArtemether-lumefantrineTreatment failureLine treatmentASAQ groupDay 28Better efficacyBurkina FasoTherapyMalariaEfficacyChain reactionCompletion ratesTreatmentDays
2019
Impact of the addition of azithromycin to antimalarials used for seasonal malaria chemoprevention on antimicrobial resistance of Streptococcus pneumoniae
Hema‐Ouangraoua S, Maiga A, Cairns M, Zongo I, Frédéric N, Yerbanga R, Tamboura B, Badji H, Gore‐Langton G, Kuepfer I, Tinto H, Sagara I, Dicko A, Sow S, Chandrahoman D, Greenwood B, Ouedraogo J. Impact of the addition of azithromycin to antimalarials used for seasonal malaria chemoprevention on antimicrobial resistance of Streptococcus pneumoniae. Tropical Medicine And International Health 2019, 24: 1442-1454. PMID: 31655020, PMCID: PMC7687265, DOI: 10.1111/tmi.13321.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionAddition of azithromycinMalaria chemopreventionNasopharyngeal swabsStreptococcus pneumoniaeAnnual malaria transmission seasonsMalaria transmission seasonResistance of pneumococciMalian childrenHospital admissionAzithromycin 1Nasal isolatesAntimalarial combinationLast administrationPneumococcal isolatesTransmission seasonDrug AdministrationAzithromycinChemopreventionResistant isolatesAntimalarialsAntimicrobial resistancePlaceboBurkina FasoChildren
2018
Serum Carotenoids Reveal Poor Fruit and Vegetable Intake among Schoolchildren in Burkina Faso
Bationo J, Zeba A, Abbeddou S, Coulibaly N, Sombier O, Sheftel J, Bassole I, Barro N, Ouedraogo J, Tanumihardjo S. Serum Carotenoids Reveal Poor Fruit and Vegetable Intake among Schoolchildren in Burkina Faso. Nutrients 2018, 10: 1422. PMID: 30287727, PMCID: PMC6213241, DOI: 10.3390/nu10101422.Peer-Reviewed Original ResearchConceptsSerum retinol concentrationsSerum carotenoidsRetinol concentrationsVegetable intakeLow serum carotenoidsSerum carotene concentrationSerum carotenoid concentrationsTotal serum carotenoid concentrationsLow serum vitaminCross-sectional studyIndividual carotenoid concentrationsΒ-cryptoxanthinHabitual intakeSerum vitaminHigh prevalenceLow intakeReference rangeVitamin A.IntakeHealth benefitsRich fruitsCarotenoid concentrationsBurkina FasoHigh-performance liquid chromatographySchoolchildrenAntibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
Yaro S, Lafourcade B, Ouangraoua S, Ouoba A, Kpoda H, Findlow H, Tall H, Seanehia J, Martin C, Ouedraogo J, Gessner B, Meda N, Borrow R, Trotter C, Mueller J. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign? Clinical Infectious Diseases 2018, 68: 435-443. PMID: 30481265, DOI: 10.1093/cid/ciy488.Peer-Reviewed Original ResearchConceptsPre-vaccination levelsAge groupsBooster campaignAntibody persistenceMeningococcal serogroup A conjugate vaccineSerum bactericidal antibody titersBactericidal antibody titersYounger age groupsOlder age groupsImmunoglobulin G concentrationCross-sectional surveyTime of returnDifferent age groupsConjugate vaccineAntibody titersImmune protectionGeneral populationMass vaccinationSerological surveyComplete returnOlder individualsMass campaignsBurkina FasoGeometric meanBobo-DioulassoPlasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso
Somé A, Bazié T, Zongo I, Yerbanga R, Nikiéma F, Neya C, Taho L, Ouédraogo J. Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso. Parasites & Vectors 2018, 11: 323. PMID: 29843783, PMCID: PMC5975679, DOI: 10.1186/s13071-018-2895-4.Peer-Reviewed Original ResearchConceptsSymptomatic malaria patientsPolymerase chain reactionMalaria patientsAllelic familiesBobo-DioulassoMAD20 allelic familyUrban health centersCause of morbidityMerozoite surface protein 1K1 allelic familySurface protein 1Plasmodium falciparum msp1P. malariaUncomplicated malariaFalciparum infectionResultsA totalHealth centersBlood samplesP. falciparumConclusionsOur studyBlood spotsMalaria parasite populationsAllele frequenciesPatientsBurkina Faso
2017
Predictors and pathways of language and motor development in four prospective cohorts of young children in Ghana, Malawi, and Burkina Faso
Prado E, Abbeddou S, Adu‐Afarwuah S, Arimond M, Ashorn P, Ashorn U, Bendabenda J, Brown K, Hess S, Kortekangas E, Lartey A, Maleta K, Oaks B, Ocansey E, Okronipa H, Ouédraogo J, Pulakka A, Somé J, Stewart C, Stewart R, Vosti S, Jimenez E, Dewey K. Predictors and pathways of language and motor development in four prospective cohorts of young children in Ghana, Malawi, and Burkina Faso. Journal Of Child Psychology And Psychiatry 2017, 58: 1264-1275. PMID: 28543426, PMCID: PMC5697619, DOI: 10.1111/jcpp.12751.Peer-Reviewed Original ResearchConceptsEarly child developmentIron statusMotor developmentProspective cohortPonderal growthAcute respiratory infectionsInternational LipidMaternal illnessExclusive breastfeedingMiddle-income countriesRespiratory infectionsPrevious reviewsMonths postpartumRisk factorsChild diarrheaCohortDesign of interventionsSocioeconomic statusCaregiver activitiesChild developmentPregnancyYoung childrenBurkina FasoDietary diversityChildrenTO VALUE THE EFFICIENCY OF PYRONARIDINE-ARTESUNATE AND ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED MALARIA OF PLASMODIUM SPP. IN BURKINA FASO
Barry N, Kaboré N, Kabré Z, Fofana A, Nikèma F, Compaoré D, Somé F, Zongo I, Djimdé A, Ouédraogo J. TO VALUE THE EFFICIENCY OF PYRONARIDINE-ARTESUNATE AND ARTEMETHER-LUMEFANTRINE IN THE TREATMENT OF UNCOMPLICATED MALARIA OF PLASMODIUM SPP. IN BURKINA FASO. BMJ Global Health 2017, 2: a24. DOI: 10.1136/bmjgh-2016-000260.62.Peer-Reviewed Original ResearchArtemether-lumefantrineUncomplicated malariaTreatment failurePA groupAL groupEffective malaria vaccineStandard of careNew therapeutic drugsPyronaridine-ArtesunateMalaria vaccinePatient groupTherapeutic failureFirst episodeTreatment responseDay 28Malaria diagnosisDay 42Burkina FasoMalaria controlEvidence baseLess casesPlasmodium sppTherapeutic drugsMalariaBobo-Dioulasso
2016
Linear Growth and Child Development in Burkina Faso, Ghana, and Malawi
Prado E, Abbeddou S, Adu-Afarwuah S, Arimond M, Ashorn P, Ashorn U, Brown K, Hess S, Lartey A, Maleta K, Ocansey E, Ouédraogo J, Phuka J, Somé J, Vosti S, Jimenez E, Dewey K. Linear Growth and Child Development in Burkina Faso, Ghana, and Malawi. Pediatrics 2016, 138: e20154698. PMID: 27474016, DOI: 10.1542/peds.2015-4698.Peer-Reviewed Original ResearchConceptsPersonal-social developmentDevelopmental stimulationAge z-scoreAge 18 monthsMaternal supplementationLinear growthNutritional supplementationGrowth falteringEarly infancyZ-scoreMotor developmentAdjusted estimatesBurkina FasoMonthsBirthChild developmentMotor skillsChildrenSDAssociationExecutive functionSupplementationStimulationExecutive function developmentPoor development